As ATM mutations and loss of ATM expression can be found in hereditary and sporadic breast cancers and A-T heterozygotes can be diagnosed [23], we hypothesized that such data might be useful in extending the molecular predictors required for selecting patients responsive to PARP inhibition. This evidence concerns the gene PARP1 and breast carcinoma.